Rubric Capital Management LP bought $90k of TXMD
owner at TherapeuticsMD, Inc.. 14,825 shares at an average of $6.09, traded Dec 9, 2022, filed Dec 12, 2022.
Score components
- +12Role10% owner
- +9Trade size$90k at market
- -5Relative to holdingsUnder 1% of holdings (0.9%)
- +8Price context73% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-22-126117, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2022 | POpen-market purchase Common Stock, par value $0.001 per share ("Common Stock")indirect: See footnote | +14,825 | $6.09 | $90k | 1,757,191 | Dec 12, 2022 |
Related signals
Other insiders at TherapeuticsMD, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | TXMDbuy TherapeuticsMD, Inc. | Tommy G Thompson director | $14k 8,400 shares | +57% | |
| 33Weak | TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $489 490 shares | +1% | |
| 23Weak | TherapeuticsMD, Inc. | Tommy G Thompson director | $326 325 shares | +2% | |
| 33Weak | TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $1,994 2,303 shares | +3% | |
| 31Weak | TXMDbuy TherapeuticsMD, Inc. | Cooper C. Collins director | $7,099 4,094 shares | +9% | |
| 23Weak | TXMDbuy TherapeuticsMD, Inc. | Cooper C. Collins director | $2,039 1,200 shares | +3% | |
| 21Weak | TXMDsell TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $44k 19,050 shares | -23% | |
| 5Weak | TXMDsell TherapeuticsMD, Inc. | Michael C Donegan Prin. Fin. and Acctg. Officer | $8,621 1,697 shares | -13% | |
| 5Weak | TXMDsell TherapeuticsMD, Inc. | Michael C Donegan Prin. Fin. and Acctg. Officer | $6,988 1,309 shares | -15% | |
| 30Weak | TherapeuticsMD, Inc. | Brian Bernick Co-Chief Executive Officer | $6,621 1,255 shares | -24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.